Tear Sheet

Company Overview

HTG’s mission is to advance the promise of precision medicine through innovative transcriptome-wide profiling technology designed to accelerate the development of diagnostics and hasten the discovery of novel drug candidates to effect lifechanging outcomes. Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. 

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration
HTG’s Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies TUCSON, Ariz. , Nov. 17, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling
Toggle Summary HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that, on November 9, 2021 the Compensation Committee of the
Toggle Summary HTG Molecular Diagnostics Reports Third Quarter 2021 Results
Call scheduled for today, November 10, at 4:30 pm ET TUCSON, Ariz. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its
Toggle Summary HTG Molecular Diagnostics to Announce Third Quarter 2021 Financial Results and Host Conference Call on Wednesday, November 10
TUCSON, Ariz. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company advancing precision medicine through its transcriptome-wide technology, today announced that it will report its financial results for the third quarter ended September 30, 2021
Toggle Summary HTG Expands Therapeutics Team
Veteran Drug Developer Stephen Barat, Ph.D. Joins to Head Company’s Therapeutics Division TUCSON, Ariz. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Quarterly report which provides a continuing view of a company's financial position

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities